Does the media favor BEAM or ORIC?

In the previous week, Beam Therapeutics had 4 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for Oric Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.62 beat Oric Pharmaceuticals' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Beam Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is ORIC or DNLI more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Denali Therapeutics N/A -52.20% -43.86%

Does the media refer more to ORIC or DNLI?

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 0.13 beat Oric Pharmaceuticals' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Denali Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, ORIC or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A Telix Pharmaceuticals $803.79M 3.89 -$7.12M N/A N/A

Is ORIC or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Telix Pharmaceuticals N/A N/A N/A

Does the media refer more to ORIC or TLX?

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 2 articles in the media. Telix Pharmaceuticals' average media sentiment score of 0.12 beat Oric Pharmaceuticals' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Telix Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ORIC or DYN?

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Oric Pharmaceuticals N/A N/A -$129.47M -$1.44 N/A Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A

Is ORIC or DYN more profitable?

Oric Pharmaceuticals' return on equity of -35.33% beat Dyne Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Oric Pharmaceuticals N/A -35.33% -33.31% Dyne Therapeutics N/A -58.28% -46.77%

Does the media prefer ORIC or DYN?

In the previous week, Dyne Therapeutics had 7 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 9 mentions for Dyne Therapeutics and 2 mentions for Oric Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.65 beat Oric Pharmaceuticals' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Dyne Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ORIC or RCUS?

In the previous week, Arcus Biosciences had 20 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 22 mentions for Arcus Biosciences and 2 mentions for Oric Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.89 beat Oric Pharmaceuticals' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Oric Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arcus Biosciences 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Oric Pharmaceuticals (ORIC) Competitors

$7.53 +0.03 (+0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$7.72 +0.19 (+2.59%)

As of 07:46 PM Eastern

Compare

ORIC vs. BEAM, DNLI, TLX, DYN, and RCUS

Should you buy Oric Pharmaceuticals stock or one of its competitors? MarketBeat compares Oric Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Oric Pharmaceuticals include Beam Therapeutics (BEAM), Denali Therapeutics (DNLI), Telix Pharmaceuticals (TLX), Dyne Therapeutics (DYN), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry.

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Beam Therapeutics (NASDAQ:BEAM) and Oric Pharmaceuticals (NASDAQ:ORIC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Beam Therapeutics has a beta of 2.25, suggesting that its share price is 125% more volatile than the broader market. Comparatively, Oric Pharmaceuticals has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Beam Therapeutics currently has a consensus price target of $46.83, suggesting a potential upside of 57.26%. Oric Pharmaceuticals has a consensus price target of $19.36, suggesting a potential upside of 157.15%. Given Oric Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Beam Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Beam Therapeutics	1 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.71
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Beam Therapeutics has higher revenue and earnings than Oric Pharmaceuticals. Beam Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Beam Therapeutics	$139.74M	21.92	-$79.99M	-$0.68	N/A
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A

In the previous week, Beam Therapeutics had 4 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 6 mentions for Beam Therapeutics and 2 mentions for Oric Pharmaceuticals. Beam Therapeutics' average media sentiment score of 0.62 beat Oric Pharmaceuticals' score of 0.00 indicating that Beam Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Beam Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of Beam Therapeutics shares are held by institutional investors. Comparatively, 95.1% of Oric Pharmaceuticals shares are held by institutional investors. 3.8% of Beam Therapeutics shares are held by insiders. Comparatively, 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Oric Pharmaceuticals has a net margin of 0.00% compared to Beam Therapeutics' net margin of -39.66%. Beam Therapeutics' return on equity of -29.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Beam Therapeutics	-39.66%	-29.00%	-22.61%
Oric Pharmaceuticals	N/A	-35.33%	-33.31%

Summary

Beam Therapeutics beats Oric Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Denali Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Denali Therapeutics (NASDAQ:DNLI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Oric Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Denali Therapeutics is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Denali Therapeutics	$330.53M	9.38	-$512.54M	-$2.88	N/A

Oric Pharmaceuticals' return on equity of -35.33% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Denali Therapeutics	N/A	-52.20%	-43.86%

Oric Pharmaceuticals presently has a consensus price target of $19.36, suggesting a potential upside of 157.15%. Denali Therapeutics has a consensus price target of $34.25, suggesting a potential upside of 75.28%. Given Oric Pharmaceuticals' higher possible upside, equities analysts plainly believe Oric Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Denali Therapeutics	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 12.5% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 2 articles in the media. Denali Therapeutics' average media sentiment score of 0.13 beat Oric Pharmaceuticals' score of 0.00 indicating that Denali Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Denali Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Oric Pharmaceuticals has a beta of 1.04, suggesting that its stock price is 4% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.03, suggesting that its stock price is 3% more volatile than the broader market.

Summary

Oric Pharmaceuticals beats Denali Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Oric Pharmaceuticals (NASDAQ:ORIC) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, institutional ownership and profitability.

Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, meaning that its stock price is 110% less volatile than the broader market.

Telix Pharmaceuticals' return on equity of 0.00% beat Oric Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Oric Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Telix Pharmaceuticals	$803.79M	3.89	-$7.12M	N/A	N/A

Oric Pharmaceuticals currently has a consensus target price of $19.36, indicating a potential upside of 157.15%. Telix Pharmaceuticals has a consensus target price of $21.13, indicating a potential upside of 129.12%. Given Oric Pharmaceuticals' higher possible upside, research analysts plainly believe Oric Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

95.1% of Oric Pharmaceuticals shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Oric Pharmaceuticals and Oric Pharmaceuticals both had 2 articles in the media. Telix Pharmaceuticals' average media sentiment score of 0.12 beat Oric Pharmaceuticals' score of 0.00 indicating that Telix Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Telix Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Telix Pharmaceuticals beats Oric Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Oric Pharmaceuticals (NASDAQ:ORIC) and Dyne Therapeutics (NASDAQ:DYN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Oric Pharmaceuticals' return on equity of -35.33% beat Dyne Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Dyne Therapeutics	N/A	-58.28%	-46.77%

Oric Pharmaceuticals presently has a consensus price target of $19.36, indicating a potential upside of 157.15%. Dyne Therapeutics has a consensus price target of $35.00, indicating a potential upside of 108.21%. Given Oric Pharmaceuticals' higher probable upside, research analysts clearly believe Oric Pharmaceuticals is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	3 Strong Buy rating(s)	2.94

Oric Pharmaceuticals has a beta of 1.04, meaning that its stock price is 4% more volatile than the broader market. Comparatively, Dyne Therapeutics has a beta of 1.09, meaning that its stock price is 9% more volatile than the broader market.

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 9.5% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, Dyne Therapeutics had 7 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 9 mentions for Dyne Therapeutics and 2 mentions for Oric Pharmaceuticals. Dyne Therapeutics' average media sentiment score of 0.65 beat Oric Pharmaceuticals' score of 0.00 indicating that Dyne Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Dyne Therapeutics	2 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Oric Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A

Summary

Dyne Therapeutics beats Oric Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Oric Pharmaceuticals compare to Arcus Biosciences?

Oric Pharmaceuticals (NASDAQ:ORIC) and Arcus Biosciences (NYSE:RCUS) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, dividends, risk, valuation, earnings and institutional ownership.

In the previous week, Arcus Biosciences had 20 more articles in the media than Oric Pharmaceuticals. MarketBeat recorded 22 mentions for Arcus Biosciences and 2 mentions for Oric Pharmaceuticals. Arcus Biosciences' average media sentiment score of 0.89 beat Oric Pharmaceuticals' score of 0.00 indicating that Arcus Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Oric Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arcus Biosciences	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

95.1% of Oric Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Arcus Biosciences shares are held by institutional investors. 5.7% of Oric Pharmaceuticals shares are held by insiders. Comparatively, 9.6% of Arcus Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Oric Pharmaceuticals has higher earnings, but lower revenue than Arcus Biosciences. Arcus Biosciences is trading at a lower price-to-earnings ratio than Oric Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oric Pharmaceuticals	N/A	N/A	-$129.47M	-$1.44	N/A
Arcus Biosciences	$247M	11.84	-$353M	-$3.18	N/A

Oric Pharmaceuticals has a beta of 1.04, indicating that its stock price is 4% more volatile than the broader market. Comparatively, Arcus Biosciences has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market.

Oric Pharmaceuticals presently has a consensus target price of $19.36, suggesting a potential upside of 157.15%. Arcus Biosciences has a consensus target price of $35.10, suggesting a potential upside of 50.94%. Given Oric Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Oric Pharmaceuticals is more favorable than Arcus Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oric Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Arcus Biosciences	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Oric Pharmaceuticals has a net margin of 0.00% compared to Arcus Biosciences' net margin of -156.36%. Oric Pharmaceuticals' return on equity of -35.33% beat Arcus Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oric Pharmaceuticals	N/A	-35.33%	-33.31%
Arcus Biosciences	-156.36%	-68.97%	-35.27%

Summary

Oric Pharmaceuticals beats Arcus Biosciences on 10 of the 14 factors compared between the two stocks.

Get Oric Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORIC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORIC vs. The Competition

Export

Metric	Oric Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$776.38M	$3.30B	$6.43B	$12.05B
Dividend Yield	N/A	2.31%	2.67%	5.56%
P/E Ratio	N/A	18.93	23.75	23.75
Price / Sales	N/A	173.93	479.99	83.74
Price / Cash	N/A	51.45	26.99	37.25
Price / Book	1.93	8.04	10.28	6.78
Net Income	-$129.47M	$23.89M	$3.57B	$337.51M
7 Day Performance	-16.15%	-5.97%	-1.43%	-2.72%
1 Month Performance	-14.92%	2.78%	3.27%	1.87%
1 Year Performance	-19.21%	36.26%	23.37%	26.61%

Oric Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORIC Oric Pharmaceuticals	1.9827 of 5 stars	$7.53 +0.4%	$19.36 +157.2%	-19.5%	$776.38M	N/A	N/A	80	Analyst Forecast
BEAM Beam Therapeutics	2.5285 of 5 stars	$31.14 -5.4%	$46.83 +50.4%	+58.2%	$3.39B	$164.01M	N/A	510	Gap Up
DNLI Denali Therapeutics	3.2848 of 5 stars	$20.41 -3.0%	$34.25 +67.8%	+32.8%	$3.34B	N/A	N/A	430
TLX Telix Pharmaceuticals	4.5057 of 5 stars	$9.42 -0.1%	$21.13 +124.3%	-44.5%	$3.20B	$803.79M	N/A	1,184
DYN Dyne Therapeutics	3.1239 of 5 stars	$18.63 -3.6%	$35.00 +87.9%	+15.9%	$3.20B	N/A	N/A	100

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORIC) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. BEAM, DNLI, TLX, DYN, and RCUS

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Summary

How does Oric Pharmaceuticals compare to Arcus Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Oric Pharmaceuticals (ORIC) Competitors

ORIC vs. BEAM, DNLI, TLX, DYN, and RCUS

How does Oric Pharmaceuticals compare to Beam Therapeutics?

Which has more volatility & risk, BEAM or ORIC?

Do analysts prefer BEAM or ORIC?

Which has higher valuation and earnings, BEAM or ORIC?

Does the media favor BEAM or ORIC?

Do institutionals & insiders hold more shares of BEAM or ORIC?

Is BEAM or ORIC more profitable?

Summary

How does Oric Pharmaceuticals compare to Denali Therapeutics?

Which has higher earnings and valuation, ORIC or DNLI?

Is ORIC or DNLI more profitable?

Do analysts recommend ORIC or DNLI?

Do institutionals & insiders have more ownership in ORIC or DNLI?

Does the media refer more to ORIC or DNLI?

Which has more risk and volatility, ORIC or DNLI?

Summary

How does Oric Pharmaceuticals compare to Telix Pharmaceuticals?

Which has more risk & volatility, ORIC or TLX?

Is ORIC or TLX more profitable?

Which has stronger earnings & valuation, ORIC or TLX?

Do analysts rate ORIC or TLX?

Do institutionals & insiders hold more shares of ORIC or TLX?

Does the media refer more to ORIC or TLX?

Summary

How does Oric Pharmaceuticals compare to Dyne Therapeutics?

Is ORIC or DYN more profitable?

Do analysts rate ORIC or DYN?

Which has more volatility & risk, ORIC or DYN?

Do institutionals and insiders hold more shares of ORIC or DYN?

Does the media prefer ORIC or DYN?

Which has better earnings and valuation, ORIC or DYN?

Summary

How does Oric Pharmaceuticals compare to Arcus Biosciences?

Does the media refer more to ORIC or RCUS?

Do insiders & institutionals hold more shares of ORIC or RCUS?

Which has higher earnings and valuation, ORIC or RCUS?

Which has more risk and volatility, ORIC or RCUS?

Do analysts prefer ORIC or RCUS?

Is ORIC or RCUS more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORIC vs. The Competition

Oric Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools